Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Microbot MedicalMBOT 21 Revenue per Share is $0.01 as of Jun. 2026. GuruFocus rates MBOT with a GF Score™ of 21/100. The stock has 3 warning signs investors should review. Among 759 Medical Devices & Instruments companies, Microbot Medical ranks worse than 131752.17% on this metric.
Microbot Medical's revenue per share for the
three
months ended in Jun. 2026 was $0.00.
Microbot Medical's revenue per share for the trailing twelve months (TTM) ended in Jun. 2026 was $0.01.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Microbot Medical's Revenue per Share or its related term are showing as below:
During the past 13 years, Microbot Medical's highest 3-Year average Revenue Per Share Growth Rate was 150.10% per year. The lowest was -80.90% per year. And the median was -37.20% per year.
MBOT's 3-Year Revenue Growth Rate is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 3.7 * Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Microbot Medical Revenue per Share Related Terms
Microbot Medical Revenue per Share Historical Data
* Premium members only.
The historical data trend for Microbot Medical's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MBOT vs LNSR, LUNG, ECOR: Revenue per Share Comparison
For the Medical Devices subindustry, Microbot Medical's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Microbot Medical PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Microbot Medical's PS Ratio distribution charts can be found below:
* The bar in red indicates where Microbot Medical's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Microbot Medical's Revenue Per Share for the fiscal year that ended in Dec. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Microbot Medical (MBOT) has a Revenue per Share of $0.01 as of Jun. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on Microbot Medical and its competitors. According to the industry distribution chart, Microbot Medical ranks #999999 out of 759 companies in the Medical Devices & Instruments industry.
Is Microbot Medical's Revenue per Share too high?
Microbot Medical's current Revenue per Share is $0.01. The Medical Devices & Instruments industry median Revenue per Share is 3.70. Microbot Medical's value of $0.01 is 99.7% below this industry median. Based on the distribution chart, Microbot Medical ranks #999999 out of 759 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Microbot Medical has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Microbot Medical's Revenue per Share compare to LNSR and LUNG?
According to the Medical Devices & Instruments industry distribution chart, Microbot Medical ranks #999999 out of 759 companies for Revenue per Share. This places Microbot Medical in the lower half of its industry. The industry median Revenue per Share is 3.70. Microbot Medical's value of $0.01 is 99.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Medical Devices & Instruments company?
The median Revenue per Share among Medical Devices & Instruments companies is 3.70, based on 759 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Microbot Medical's current Revenue per Share of $0.01 is 99.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Microbot Medical and its competitors. For the Medical Devices & Instruments industry, the median Revenue per Share is 3.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Microbot Medical's current Revenue per Share is $0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microbot Medical stock overvalued right now?
Microbot Medical (MBOT) has a current Revenue per Share of $0.01. The current Revenue per Share is $0.01 and 99.7% below the Medical Devices & Instruments industry median of 3.70. Microbot Medical's overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Microbot Medical (MBOT), the current Revenue per Share is $0.01 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Microbot Medical Inc is a medical device company specializing in the research, design, and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, the company has developed the LIBERTY Endovascular Robotic Surgical System, a fully disposable robot for various endovascular interventional procedures. The company has a single operating and reportable segment, which is the development of robotic devices for endoluminal surgery.
21GF Score
Get the complete analysis for MBOT
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MBOT has been successfully added to your 
